ARK Genomic Revolution ETF (BATS:ARKG) Hits New 12-Month High – What’s Next?

ARK Genomic Revolution ETF (BATS:ARKG)’s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $42.34 and last traded at $42.08, with a volume of 655870 shares trading hands. The stock had previously closed at $41.43.

ARK Genomic Revolution ETF Stock Performance

The stock’s 50-day moving average is $32.38 and its 200-day moving average is $30.33.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. JPMorgan Chase & Co. raised its stake in shares of ARK Genomic Revolution ETF by 30.6% in the 4th quarter. JPMorgan Chase & Co. now owns 5,149,454 shares of the company’s stock valued at $149,180,000 after buying an additional 1,205,541 shares in the last quarter. Morgan Stanley boosted its position in ARK Genomic Revolution ETF by 42.2% in the fourth quarter. Morgan Stanley now owns 4,025,965 shares of the company’s stock valued at $116,632,000 after buying an additional 1,193,795 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of ARK Genomic Revolution ETF by 49.7% in the 4th quarter. BNP Paribas Financial Markets now owns 3,514,980 shares of the company’s stock worth $101,829,000 after acquiring an additional 1,167,558 shares in the last quarter. Wells Fargo & Company MN boosted its stake in ARK Genomic Revolution ETF by 29.1% in the fourth quarter. Wells Fargo & Company MN now owns 1,287,390 shares of the company’s stock worth $37,296,000 after purchasing an additional 290,301 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in ARK Genomic Revolution ETF by 185.0% during the 4th quarter. Royal Bank of Canada now owns 445,592 shares of the company’s stock worth $12,910,000 after acquiring an additional 289,237 shares during the last quarter.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.